AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

It’s only February, but my pick for the Worst Biopharma CEO of 2025 has already been decided: Albert Bourla of Pfizer. Pfizer’s decision to hire Patrizia Cavazzoni, a former top drug ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...

Pharmaceuticals and life science is such a big space, whether that is in health and safety training in factories or laboratories.” For Pfizer, immersive technology is about the accessibility and ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Beqvez brings an inauspicious ending to a gene therapy that got its start more than a decade ago in the labs of Spark Therapeutics in Philadelphia. Pfizer's disclosure Friday that it is ending ...

In 2007 and 2008, Holmes conducted a study for Pfizer investigating the angiogenesis ... companies reagent that is used by LabCorp and many labs across the nation called, R&D Systems VEGF ELISA.

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer’s future ...

China’s Asymchem Laboratories has agreed to take over the operation of a Pfizer UK manufacturing facility in Sandwich, Kent, safeguarding dozens of jobs. The Tianjin-headquartered contract ...

Shares of Pfizer (NYSE:PFE) have delivered negative returns since I started covering the stock and the last four months have not been great either as it is down another 12% since my previous ...

Pfizer's longstanding dominance of the pneumococcal ... head of global clinical development and chief medical officer at Merck Research Laboratories. "These results support the potential for ...